Edward J. Dulac III - 23 Jul 2025 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role
EVP, Chief Financial Officer
Signature
James Basta, attorney-in-fact
Issuer symbol
NTLA
Transactions as of
23 Jul 2025
Net transactions value
-$104,617
Form type
4
Filing time
25 Jul 2025, 16:05:06 UTC
Previous filing
04 Mar 2025
Next filing
07 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Dulac Edward J III EVP, Chief Financial Officer C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE James Basta, attorney-in-fact 25 Jul 2025 0001821530

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NTLA Common Stock Sale $104,617 -7,462 -6.6% $14.02 106,062 23 Jul 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on July 22, 2025, and does not represent a volitional trade by the Reporting Person.